Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment

Nuclear Medicine Communications

Volumn 29, Issue 11, 2008, Pages 970-981

  Santana, Cesar A ^a,b   Faber, Tracy L ^a,b   Soler Peter, Marina ^a,b   Sanyal, Rupan ^a,b   Esteves, Fabio P ^a,b   Ornelas, Mario ^a,b   Folks, Russell D ^a,b   Verdes, Liudmila ^a,b   Santana, Leonela F ^a,b   Candell Riera, Jaume ^a,b   Garcia, Ernest V ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Positron emission tomography; Prognosis; Viability

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RUBIDIUM 82;

ADULT; AGED; ARTICLE; CELL VIABILITY; DIAGNOSTIC VALUE; FEMALE; HEART DEATH; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE PERFUSION; HEART MUSCLE VIABILITY; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOISOTOPE DISTRIBUTION; SCINTIANGIOCARDIOGRAPHY;

AGED; CARDIOMYOPATHIES; CORONARY CIRCULATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEART; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; ROC CURVE; RUBIDIUM RADIOISOTOPES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 55149105647     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283073b60     Document Type: Article

References (23)

1. Marshall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E, Schelbert HR. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983; 67:766-778.
2. Garcia EV, Vansant JP. Assessment of mechanical function as an adjunct to myocardial perfusion/metabolism emission tomography studies. J Nucl Med 1994; 35:1005-1006. Editorial.
3. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884-888.
4. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73:527-533.
5. Di Carli M, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, Maddahi J. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92:3436-3444.
6. Di Carli MF. Predicting improved function after myocardial revascularization. Curr Opin Cardiol 1998; 13:415-424.
7. Maddahi J, Blitz A, Phelps M, Laks H. The use of positron emission tomography imaging in the management of patients with ischemic cardiomyopathy. Adv Card Surg 1996; 7:1663-8812.
8. Santana CA, Shaw LJ, Garcia EV, Soler-Peter M, Candell-Riera J, Grossman GB, et al. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy. J Nucl Cardiol 2004; 11:542-550.
9. Bom HS, Vansant JP, Pettigrew RI, Cooke CD, Votaw JR, Garcia EV. Determination of myocardial viability with ECG-gated fluorodeoxyglucose F-18 positron emission tomography. Clin Pos Imag 1999; 2:183-190.
10. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151-1158.
11. Eitzman D, Al-Aouar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20:559-565.
12. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: relative efficacy of medical therapy and revascularization. Circulation 1994; 90:2687-2694.
13. Wackers RJTh. Science, art and artifacts: how important is quantification for the practicing physician interpreting myocardial perfusion studies? J Nucl Cardiol 1994;1:109-117.
14. Garcia E, DePuey EG, Sonnemaker RE, Neely HR, DePasquale EE, Robbins WL, et al. quantification of the reversibility of stress induced SPECT thallium-201 myocardial perfusion defects: a multicenter trial using Bull's-eye polar maps and standard normal limits. J Nucl Med 1990; 31:1761-1765.
15. Garcia EV, Cooke CD, Folks RD, Santana CA, Krawczynska EG, De Braal L, Ezquerra NF. Diagnostic performance of an expert system for the interpretation of myocardial perfusion SPECT studies. J Nucl Med 2001; 42:1185-1191.
16. 99mTc-tetrofosmin gated SPECT. J Nucl Cardiol 2001; 8:122-128.
17. Pagano D, Bonser RS, Townend J, Ordoubadi F, Lorenzoni R, Camici P. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998; 79:281-8.
18. Beanlands RSB, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M, et al. Positron emission tomography and recovery following revascularization: the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40:1735-43.
19. Porenta G, Kuhle W, Czernin J, Ratib O, Brunken RC, Phelps ME, Schelbert HR. Semiquantitative assessment of myocardial blood flow and viability using polar map displays of cardiac PET images. J Nucl Med 1992; 33:1628-1636.
20. Faber TL, Santana CA, Garcia EV. Validation of the new PET tools for assessment of the perfusion - metabolism match-mismatch using Rb-82 and FDG-18. J Nucl Med 2002; 43:145.
21. Santana CA, Folks RD, Garcia EV, Verdes L, Hainer J, Di Carli MF, Esteves FP. Quantitative Rb-82 PET/CT: development and validation of myocardial perfusion database. J Nucl Med 2007; 48:1-7.
22. Haas F, Haehnel C, Picker W, Nekolla S, Martinoff S, Meisner H, Schwaiger M. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30:1693-700.
23. Schelbert HR. Positron emission tomography for the assessment of myocardial viability. Circulation 1991; 84:I122-I131.